0
POPSAngioplasties Drop A USA Today analysis shows that in the wake of big studies like Courage that showed a benefit for angioplasties that was lower than many expected, fewer patients are opting for the treatment to alleve chest pain. That's bad news for makers of stents, including Johnson & Johnson, Boston Scientific, Abbott, and Medtronic.